Compare Johnson & Johnson (JNJ) vs Prospect Capital Corporation (PSEC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Johnson & Johnson vs Prospect Capital Corporation — how do they compare? Johnson & Johnson trades at $260.62 (market cap $626.09B), while Prospect Capital Corporation trades at $2.29 (market cap $1.14B). The key difference: Johnson & Johnson is far larger — about 549.2× Prospect Capital Corporation's market cap, and Prospect Capital Corporation pays the higher dividend (21.93%). Which is the better fit depends on your goals.
| JNJ | PSEC | |
|---|---|---|
Market Cap | $626.09B | $1.14B |
Volume | 6,156,228 | — |
Sector | Health | Financials |
52-Week High | $267.24 | $3.05 |
52-Week Low | $172.78 | $2.11 |
Enterprise Value | $654.37B | — |
Dividend Yield | 2.06% | 21.93% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Johnson & Johnson (JNJ) trades at $261.26, down 0.21% on the day, near its 52-week high. The stock shows a bullish technical trend with strong moving averages and recent earnings beats. Revenue grew to $94.19B in 2025, with a net income margin of 21.48%, though cash flow turned negative due to heavy investing. The company maintains a robust dividend history, with consistent payouts and a 64-year growth streak.
Outlook remains positive with a consensus price target of $284.50, offering ~9% upside. Risks include legal headwinds and patent expirations, but analyst sentiment is bullish (52.5% buy ratings). JNJ's defensive profile and pipeline strength support long-term growth, though investors should monitor debt levels, which rose to 24.06% of assets in 2025.
Prospect Capital Corporation (PSEC) trades at $2.285, down 0.22% on the day, with a bullish technical signal from moving averages. The company shows mixed fundamentals with a low P/B ratio of 0.39 but negative revenue and net income margins. Recent earnings have consistently beaten expectations, and the company maintains regular dividend payments of $0.04 per share. Analyst sentiment is divided with 25% buy ratings, 55% hold, and 20% sell recommendations.
PSEC presents a high-risk, high-yield opportunity trading at a significant discount to book value. The investment case hinges on the company's ability to stabilize revenue and return to profitability while maintaining its dividend distribution. Key risks include persistent negative revenue trends, high leverage costs, and market skepticism about portfolio quality despite recent successful exits like the Valley Electric sale generating 4.8x returns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Johnson & Johnson
Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →About Prospect Capital Corporation
Prospect Capital Corp is a closed-end investment company based in the United States. Its investment objective is to generate both current income and long-term capital appreciation through debt and equity investments. The company invests primarily in senior and subordinated debt and equity of private companies for acquisitions, divestitures, growth, development, recapitalizations, and other purposes. It makes investments, including lending in private equity, sponsored transactions, directly to companies, investments in structured credit, real estate, and syndicated debt.
Read more on PSEC →
